Obesity and the pathogenesis of nonalcoholic fatty liver disease

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Standard

Obesity and the pathogenesis of nonalcoholic fatty liver disease. / Fabbrini, Elisa; Magkos, Faidon.

Treatment of the Obese Patient. 2. ed. New York : Springer New York, 2014. p. 121-135.

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Harvard

Fabbrini, E & Magkos, F 2014, Obesity and the pathogenesis of nonalcoholic fatty liver disease. in Treatment of the Obese Patient. 2 edn, Springer New York, New York, pp. 121-135. https://doi.org/10.1007/978-1-4939-1203-2_9

APA

Fabbrini, E., & Magkos, F. (2014). Obesity and the pathogenesis of nonalcoholic fatty liver disease. In Treatment of the Obese Patient (2 ed., pp. 121-135). Springer New York. https://doi.org/10.1007/978-1-4939-1203-2_9

Vancouver

Fabbrini E, Magkos F. Obesity and the pathogenesis of nonalcoholic fatty liver disease. In Treatment of the Obese Patient. 2 ed. New York: Springer New York. 2014. p. 121-135 https://doi.org/10.1007/978-1-4939-1203-2_9

Author

Fabbrini, Elisa ; Magkos, Faidon. / Obesity and the pathogenesis of nonalcoholic fatty liver disease. Treatment of the Obese Patient. 2. ed. New York : Springer New York, 2014. pp. 121-135

Bibtex

@inbook{8fb04d08ce294679b5de98f3b14fe9e0,
title = "Obesity and the pathogenesis of nonalcoholic fatty liver disease",
abstract = "Obesity is associated with increased deposition of fat in the liver (nonalcoholic fatty liver disease; NAFLD), which develops when hepatic fatty acid availability from plasma and de novo synthesis exceeds hepatic fatty acid disposal by oxidation and triglyceride export. Therefore, an increase in intrahepatic triglyceride content (steatosis) results from an imbalance between interacting metabolic events. Hepatic steatosis is associated with an array of adverse changes in glucose, fatty acid and lipoprotein metabolism, not only locally (in the liver) but also at the whole body level. These metabolic abnormalities are likely responsible for many cardiometabolic risk factors associated with NAFLD, such as insulin resistance and dyslipidemia. However, whether NAFLD is the cause of metabolic dysfunction or whether metabolic dysfunction is responsible for excessive intrahepatic triglyceride accumulation remains unclear at this time. Understanding the factors involved in the pathogenesis and pathophysiology of NAFLD will lead to a better understanding of the mechanisms responsible for the metabolic complications of obesity.",
author = "Elisa Fabbrini and Faidon Magkos",
note = "Publisher Copyright: {\textcopyright} 2014 Springer Science+Business Media New York. All rights are reserved.",
year = "2014",
doi = "10.1007/978-1-4939-1203-2_9",
language = "English",
isbn = "9781493912025",
pages = "121--135",
booktitle = "Treatment of the Obese Patient",
publisher = "Springer New York",
address = "United States",
edition = "2",

}

RIS

TY - CHAP

T1 - Obesity and the pathogenesis of nonalcoholic fatty liver disease

AU - Fabbrini, Elisa

AU - Magkos, Faidon

N1 - Publisher Copyright: © 2014 Springer Science+Business Media New York. All rights are reserved.

PY - 2014

Y1 - 2014

N2 - Obesity is associated with increased deposition of fat in the liver (nonalcoholic fatty liver disease; NAFLD), which develops when hepatic fatty acid availability from plasma and de novo synthesis exceeds hepatic fatty acid disposal by oxidation and triglyceride export. Therefore, an increase in intrahepatic triglyceride content (steatosis) results from an imbalance between interacting metabolic events. Hepatic steatosis is associated with an array of adverse changes in glucose, fatty acid and lipoprotein metabolism, not only locally (in the liver) but also at the whole body level. These metabolic abnormalities are likely responsible for many cardiometabolic risk factors associated with NAFLD, such as insulin resistance and dyslipidemia. However, whether NAFLD is the cause of metabolic dysfunction or whether metabolic dysfunction is responsible for excessive intrahepatic triglyceride accumulation remains unclear at this time. Understanding the factors involved in the pathogenesis and pathophysiology of NAFLD will lead to a better understanding of the mechanisms responsible for the metabolic complications of obesity.

AB - Obesity is associated with increased deposition of fat in the liver (nonalcoholic fatty liver disease; NAFLD), which develops when hepatic fatty acid availability from plasma and de novo synthesis exceeds hepatic fatty acid disposal by oxidation and triglyceride export. Therefore, an increase in intrahepatic triglyceride content (steatosis) results from an imbalance between interacting metabolic events. Hepatic steatosis is associated with an array of adverse changes in glucose, fatty acid and lipoprotein metabolism, not only locally (in the liver) but also at the whole body level. These metabolic abnormalities are likely responsible for many cardiometabolic risk factors associated with NAFLD, such as insulin resistance and dyslipidemia. However, whether NAFLD is the cause of metabolic dysfunction or whether metabolic dysfunction is responsible for excessive intrahepatic triglyceride accumulation remains unclear at this time. Understanding the factors involved in the pathogenesis and pathophysiology of NAFLD will lead to a better understanding of the mechanisms responsible for the metabolic complications of obesity.

U2 - 10.1007/978-1-4939-1203-2_9

DO - 10.1007/978-1-4939-1203-2_9

M3 - Book chapter

AN - SCOPUS:84929907713

SN - 9781493912025

SP - 121

EP - 135

BT - Treatment of the Obese Patient

PB - Springer New York

CY - New York

ER -

ID: 302382089